{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=79", "query": { "condition": "Gastrointestinal Carcinoma", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 2733, "total_pages": 274, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T13:50:05.377Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03412877", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Gastrointestinal/Genitourinary Cancers", "Neuroendocrine Tumors", "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 285, "start_date": "2018-09-06", "completion_date": "2029-03-23", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412877" }, { "nct_id": "NCT02704130", "title": "TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatocellular Carcinoma", "Hepatoma", "Liver Cancer, Adult", "Liver Cell Carcinoma", "Liver Cell Carcinoma, Adult" ], "interventions": [ { "name": "Transarterial embolization", "type": "DEVICE" }, { "name": "Microwave Ablation", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 8, "start_date": "2016-03", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2022-04-22", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02704130" }, { "nct_id": "NCT00273312", "title": "Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Patupilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00273312" }, { "nct_id": "NCT03386500", "title": "Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anal Cancer, Squamous Cell Carcinoma", "Radiation Exposure" ], "interventions": [ { "name": "BMX-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 24, "start_date": "2017-11-28", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386500" }, { "nct_id": "NCT00781911", "title": "A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "depot octreotide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2009-02", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00781911" }, { "nct_id": "NCT06479811", "title": "[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sinonasal Neuroendocrine Carcinoma", "Nasopharyngeal Carcinoma", "Esthesioneuroblastoma", "Olfactory Neuroblastoma", "Somatostatin Receptor Positive", "Small Cell Lung Cancers", "Pheochromocytoma/Paragangliomas", "Kidney Cancers", "Head and Neck Tumors", "Gastrointestinal Neuroendocrine Tumors" ], "interventions": [ { "name": "[212Pb]VMT-alpha-NET", "type": "DRUG" }, { "name": "[203Pb]VMT-alpha-NET", "type": "DRUG" }, { "name": "68Ga-DOTATATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 120, "start_date": "2025-08-19", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06479811" }, { "nct_id": "NCT03302858", "title": "A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HSIL, High Grade Squamous Intraepithelial Lesions", "Anal Cancer", "HPV-Related Squamous Cell Carcinoma", "Human Papilloma Virus", "Human Papillomavirus Infection", "Ain III" ], "interventions": [ { "name": "BARRX™ Anorectal Wand", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Stephen E. Goldstone", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 70, "start_date": "2017-10", "completion_date": "2020-10", "has_results": false, "last_update_posted_date": "2017-10-05", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03302858" }, { "nct_id": "NCT00372450", "title": "Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Gastrointestinal Complications" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2006-12", "completion_date": "2008-04-11", "has_results": false, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00372450" }, { "nct_id": "NCT00199862", "title": "Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Neoplasms", "Colorectal Cancer", "Colorectal Tumor", "COlorectal Carcinoma" ], "interventions": [ { "name": "Iodine-124 labeled humanized A33 (antibody)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-02", "completion_date": "2025-07-02", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00199862" }, { "nct_id": "NCT03543813", "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Head and Neck Cancer", "Non Small Cell Lung Cancer", "Diffuse Large B Cell Lymphoma", "Esophageal Cancer" ], "interventions": [ { "name": "CX-2029", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2018-06-15", "completion_date": "2023-06-01", "has_results": false, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-10-29T13:50:05.377Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543813" } ] }